

SHORT PAPER

Circulating Levels of Pro-inflammatory Cytokines in Patients with Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis

Abolghasem Hadinia¹, Amir Hossein Doustimotlagh^{2,3*}, Hamed Reza Goodarzi¹, Arash Arya⁴, Mojtaba Jafarinia¹

¹Department of Genetic, Marvdasht branch, Islamic Azad University, Marvdasht, ²Cellular and Molecular Research Center, ³Department of Clinical Biochemistry, Faculty of Medicine, Yasuj University of Medical Sciences, ⁴Internal Medicine, Yasuj University of Medical Sciences, Yasuj, Iran

ABSTRACT

Background: Pro-inflammatory cytokines are associated with systemic inflammatory responses. **Objective:** To investigate the levels of pro-inflammatory cytokines (IL-1 β , IL-6, and TNF- α) in patients with non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) compared to healthy individuals. **Methods:** This case-control study was conducted on 30 patients with NAFL, 30 patients with NASH, and 30 healthy volunteers. The plasma level of IL-1 β , IL-6, and TNF- α were determined by ELISA, and biochemical parameters were measured using colorimetric methods. **Results:** IL-1 β and IL-6 levels were significantly higher in patients with NASH compared with NAFL and control group. However, TNF- α levels had no significant variations in NAFL and NASH patients compared to the control group ($p=0.903$ and $p=0.960$, respectively). **Conclusion:** Results showed that the levels of ALT activity and pro-inflammatory cytokines were higher in patients with NASH compared to control and NAFL subjects; Therefore, steatosis and inflammation develop as a result of excessive pro-inflammatory factors in NASH.

Received: 2019-05-09, Revised: 2019-10-21, Accepted: 2019-11-08.

Citation: Hadinia A, Doustimotlagh AH, Goodarzi HR, Arya A, Jafarinia M. Circulating Levels of Pro-inflammatory Cytokines in Patients with Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. *Iran J Immunol.* 2019; 16(4):327-333. doi: 10.22034/iji.2019.80284.

Keywords: Interleukin-1 β , Interleukin-6, Non-Alcoholic Fatty Liver, Non-Alcoholic Steatohepatitis, Tumor Necrosis Factor- α

*Corresponding author: Dr. Amir Hossein Doustimotlagh, Department of Clinical Biochemistry, Faculty of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran, e-mail: amirhosseindoustimotlagh@gmail.com

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) refers to the fat accumulation within hepatocytes, with no history of alcohol abuse or other causes of secondary hepatic steatosis. This accumulation is strongly associated with obesity and metabolic syndrome (1). There are two types of non-alcoholic fatty liver disease (NAFLD), namely non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) (2). NAFL is non-inflammatory liver steatosis while NASH is hepatic steatosis associated with an inflammation not histologically distinct from alcohol steatohepatitis (3). NASH is the critical stage of NAFLD, and data have shown that 15%-20% of NASH patients develop liver cirrhosis in 10 to 20 years (4). The pathogenesis of NAFL and NASH has not been fully elucidated. Recent investigations have shown that the immune system plays an essential role in the initiation, maintenance, and progression of these diseases (5). Various immune parameters, such as cytokine level, have been studied for a better understanding of the pathophysiology of these diseases and as biomarkers for severity assessment and outcome prediction. General inflammatory biomarkers such as pro-inflammatory cytokines have been associated with the occurrence and prognosis of NAFLD (6). The interactions between cytokines and oxidative stress and lipid peroxidation play a vital role in the induction of alcoholic and nonalcoholic steatohepatitis (7). Cytokines have a critical part as mediators of injury, inflammation, fibrosis, and cirrhosis in NASH (8,9). The balance between pro-inflammatory and anti-inflammatory cytokines also seems to play a significant role in systemic, local metabolic, and inflammatory processes involved in the development of NAFL and NASH (1,10). Because cytokines play an etiologic role in liver diseases and are characterized by contradictory results, liver biopsy remains the standard gold test for the diagnosis of NASH; however, since it is invasive and not readily accepted by patients, non-invasive diagnosis by serum biomarkers are eagerly needed (11). The objective of this study was to evaluate the levels of plasma pro-inflammatory cytokines (IL-1 β , IL-6, and TNF- α) in NAFL and NASH compared to healthy individuals.

MATERIALS AND METHODS

Study Population. This case-control study was performed on 30 patients with NAFL, 30 patients with NASH and 30 healthy subjects, all recruited at the same time. The subjects of both case and control groups were matched with age, sex, and other demographic variables while none of the controls had a history of liver disease. All patients underwent liver sonography, and clinical examinations to ensure a definitive diagnosis of the disease. The inclusion criteria were no smoking or alcohol consumption of higher than 20 g/day; male patients aged 30 to 60 years, no history of any hepatic diseases such as hepatitis infections (B and C), liver cirrhosis and liver cancer, and no use of statins, anticonvulsants, isoniazid, rifampin and glucocorticoids, known to promote fatty liver disease. The body mass index (BMI) was calculated through dividing the weight by height squared (kg/m²). Five ml of antecubital vein blood was collected from each subject after overnight fasting. Blood samples were centrifuged at 3000 rpm for 10 min, and plasma aliquots were stored at -20°C for detection.

Biochemical Assays. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), triglyceride (TG), and direct bilirubin (DB) were measured using relevant diagnostic kits (Pars Azmoon Inc., Tehran, Iran).

Cytokines Analysis. The plasma samples were employed for IL-1 β , IL-6, and TNF- α measurements using a commercial ELISA kit (Karmania Pars Gene, Kerman, Iran) based on the manufacturer's instructions. The lower detection limit of the IL-1 β and TNF- α assay was 2 pg/ml, and that of IL-6 was 3 pg/ml. Absorption was measured via an ELISA reader (BioTek; Winooski, Vermont, USA) at 450 nm.

Statistical Analysis. One-way analysis of variance was used to compare data expressed as the mean \pm SEM. Associations between variables were calculated by Spearman correlation. p-value of 0.05 or less was considered as statistically significant.

RESULTS and DISCUSSION

All patients and healthy subjects were male. The mean ages of NAFL, NASH, and control subjects were 44 ± 1.84 , 44 ± 2.34 , and 38 ± 2.04 years, respectively. BMI levels showed significant differences between NASH and control group ($p=0.001$); however, NASH and NAFL cases were not significantly different in terms of BMI levels ($p=0.181$). The patients (NAFL and NASH) and the control group had differences regarding clinical and biochemical parameters. Nevertheless, significant differences existed between NASH and NAFL concerning ALT and AST levels (for ALT: 46.22 ± 5.50 in NASH Vs 28.84 ± 2.30 pg/ml in NAFL: $p=0.004$, for AST: 27.33 ± 1.62 in NASH Vs 21.15 ± 0.86 pg/ml in NAFL: $p=0.015$) and between NASH and healthy subjects regarding the level of ALT (46.22 ± 5.50 in NASH Vs 29.89 ± 2.27 pg/ml in control group: $p=0.007$), (Table 1).

Table 1. Plasma levels of biochemical parameters and demographic variables in patients and control groups.

Parameters	Control	NAFL	NASH
ALT (U/L)	29.89 ± 2.27	28.84 ± 2.30	$46.22 \pm 5.50^{a,b}$
AST (U/L)	24.73 ± 1.83	21.15 ± 0.86	27.33 ± 1.62^b
ALP (U/L)	209.94 ± 19.93	207.63 ± 17.66	229.94 ± 22.59
DB (mg/dl)	0.31 ± 0.03	0.30 ± 0.03	0.33 ± 0.03
TG (mg/dl)	145.21 ± 16.59	147.57 ± 13.19	156.00 ± 15.11
BMI (kg/m^2)	24.59 ± 0.69	26.79 ± 0.65	28.81 ± 0.99^a
Age (years)	38.66 ± 2.04	44.00 ± 1.84	44.00 ± 2.34

ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; DB: direct bilirubin; TG: triglyceride. Each value represents the mean \pm SEM. NAFL: non-alcoholic fatty liver; NASH: non-alcoholic steatohepatitis. ^aSignificantly different from control group, $p\text{-value} \leq 0.05$. ^bSignificantly different from NAFL group, $p\text{-value} \leq 0.05$.

After analyzing the plasma cytokine levels in patients and controls, we found that IL-1 β was significantly higher in NASH patients (5.01 ± 0.40 pg/ml) compared with NAFL (4.00 ± 0.16 pg/ml, $p=0.004$) and controls (3.73 ± 0.15 pg/ml, $p=0.026$). Furthermore, IL-6 level was significantly higher in NASH patients (4.64 ± 0.16 pg/ml) as compared to NAFL (4.19 ± 0.07 pg/ml, $p=0.004$) and control group (4.24 ± 0.05 pg/ml, $p=0.013$).

On the contrary, TNF- α levels had no significant variations in NAFL (6.69 ± 0.92 pg/ml) and NASH patients (6.04 ± 0.95 pg/ml) in comparison with the control group (5.63 ± 1.23 pg/ml) ($p=0.903$ and $p=0.960$). However, there was no significant difference between NAFL and control group regarding IL-1 β , IL-6, and TNF- α levels (Table 2).

Table 2. Plasma levels of pro-inflammatory cytokines in patients and control groups.

Cytokines	Control	NAFL	NASH
IL-1 β (pg/ml)	3.73 ± 0.15	4.00 ± 0.16	$5.01 \pm 0.40^{a,b}$
IL-6 (pg/ml)	4.24 ± 0.05	4.19 ± 0.07	$4.64 \pm 0.16^{a,b}$
TNF- α (pg/ml)	6.04 ± 0.95	6.69 ± 0.92	5.63 ± 1.23

IL-1 β : Interleukin-1 β ; IL-6: Interleukin-6; TNF- α : Tumor necrosis factor- α . Each value represents the mean \pm SEM. NAFL: non-alcoholic fatty liver; NASH: non-alcoholic steatohepatitis. ^aSignificantly different from control group, p -value ≤ 0.05 . ^bSignificantly different from NAFL group, p -value ≤ 0.05 .

Further observed were statistically significant correlations between plasma TG and ALT activity, plasma TG, and BMI, as well as ALT activity and BMI. Moreover, positive correlations were observed between the plasma levels of inflammatory cytokines (IL-6, TNF- α , and IL-1 β). However, our findings did not show significant correlations between the plasma levels of inflammatory cytokines (IL-6, TNF- α , and IL-1 β) and ALT activity or TG plasma levels (Table 3).

Table 3. Statistical significant correlations between studied parameters.

Correlation Between	Correlation coefficient	p-value
TG plasma levels and ALT activity	0.276	0.048
TG plasma levels and BMI	0.377	0.006
TG and IL-6 plasma levels	-0.011	NS*
TG and TNF- α plasma levels	-0.148	NS*
TG and IL-1 β plasma levels	-0.247	NS*
BMI and ALT activity	0.562	0.000
ALT activity and IL-6 plasma level	0.131	NS*
ALT activity and TNF- α plasma level	-0.222	NS*
ALT activity and IL-1 β plasma level	-0.151	NS*
IL-6 and TNF- α plasma levels	0.356	0.010
IL-6 and IL-1 β plasma levels	0.384	0.040
TNF- α and IL-1 β plasma levels	0.495	0.000

*NS; Not significant

The pathogenesis of NAFL and NASH is highly convoluted (12). Pro-inflammatory cytokines play a pathophysiological role in the progression of NAFL and NASH through the induction of liver inflammation, apoptosis and fibrosis (13). Our findings showed that the levels of pro-inflammatory cytokines, including IL-6, TNF- α , and IL-1 β

were not significantly different between NAFL and control subjects; however, IL-6 and IL-1 β significantly increased in NASH patients as compared to the controls and NAFL subjects. According to the present results, NAFL is a condition without inflammation while NASH is a disorder with inflammation. The role of IL-6 in fatty liver disease is also very complex, and its involvement in the progression of NAFLD is yet to be clarified (13). Numerous studies have demonstrated that the levels of IL-6 are higher in patients and animal models with NAFLD as compared to normal subjects (7,14,15). Mas *et al.* showed that diet-induced NASH was reduced in IL-6 knockout mice compared with the controls (16). In humans with NASH, a positive correlation was observed between IL-6 expression in hepatocytes and the severity of NAFLD (12,13). Yamaguchi *et al.* illustrated the paradoxical role of IL-6 in NAFLD (17). Therefore, we cannot exclude the possibility that IL-6 might also play an indirect deleterious role in NAFLD and NASH pathogenesis; however, its exact role in the pathogenesis of NAFLD and NASH remains to be specified. Several studies have demonstrated that IL-1 β , in many ways, contributes to the development of NAFLD (18-20). Kumar *et al.* reported that IL-1 plasma levels were significantly higher among NAFLD patients compared to other chronic liver diseases, with significantly high levels in the advanced stage of fibrosis (21). In a diet-induced model of steatosis/steatohepatitis, an increase was observed in the hepatic expression of IL-1 α / β (12). TNF- α is a main factor in the progression of NAFL and NASH. Hotamisligil *et al.* reported a correlation between the expressions of TNF- α and insulin resistance in NASH subjects (22). Although the inhibition of TNF- α in NAFLD animal model is a therapeutic approach, the role of this cytokine in humans remains controversial. Moreover, a positive correlation was reported between TNF- α level and the degree of liver fibrosis in NASH patients (23). Zahran *et al.* showed that TNF- α was increased in NAFLD patients compared to the control group (24). In a cross-sectional study by Hui *et al.*, TNF- α levels were found to be significantly higher in NAFL patients compared to the controls; however, there existed no significant difference in terms of TNF- α levels between NAFL and NASH as diagnosed by liver biopsy (25). However, the role of TNF- α in NAFLD and insulin resistance is questionable. Lucero *et al.* did not observe any difference in the serum levels of TNF- α between NAFLD patients and healthy subjects (26). In another study, Musso *et al.* reported no significant differences concerning TNF- α serum levels among obese, nondiabetic NASH patients, and matched controls (27). Among all pro-inflammatory cytokines involved in the pathogenesis of NAFLD, TNF- α is the most commonly characterized by conflicting results. This is probably ascribed to the heterogeneity in study populations or various factors that might affect the plasma levels of TNF- α , sample sizes and factors that possibly interfere with plasma TNF- α level detection (1,28). The role of the TNF- α in NAFLD needs to be corroborated in future studies. In conclusion, pro-inflammatory cytokines did not differ between NAFL and control subjects, suggesting that the clinical data pertaining to the early stage of NAFLD (NAFL) are similar to healthy subjects; moreover, steatosis and inflammation develop in response to excessive pro-inflammatory factors in NASH patients. Furthermore, high plasma levels of IL-1 β and IL-6 imply a systemic inflammation. Consequently, pro-inflammatory cytokines may induce an essential correlation between metabolic and liver disorders in fat accumulation and liver fibrosis.

ACKNOWLEDGEMENTS

The study was financially supported by Deputy of Research and Technology of Yasuj University of Medical Sciences (Grant No: 960161), Yasuj, Iran.

REFERENCES

1. Stojšavljević S, Palčić MG, Jukić LV, Duvnjak LS, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. *World J Gastroenterol.* 2014; 20:18070.
2. Borrelli A, Bonelli P, Tuccillo FM, Goldfine ID, Evans JL, Buonaguro FM, et al. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. *Redox Biol.* 2018; 15:467-479.
3. Bellentani S. The epidemiology of non-alcoholic fatty liver disease. *Liver Int.* 2017; 37 Suppl 1:81-84.
4. Yang M, Xu D, Liu Y, Guo X, Li W, Guo C, et al. Combined serum biomarkers in non-invasive diagnosis of non-alcoholic steatohepatitis. *PLoS One.* 2015; 10:e0131664.
5. Harley IT, Stankiewicz TE, Giles DA, Softic S, Flick LM, Cappelletti M, et al. IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. *Hepatology.* 2014; 59:1830-9.
6. Paquissi FC. Immune imbalances in non-alcoholic fatty liver disease: from general biomarkers and neutrophils to interleukin-17 axis activation and new therapeutic targets. *Front Immunol.* 2016; 7:490.
7. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. *Hepatology.* 2003; 38:413-9.
8. Bocsan IC, Milaciu MV, Pop RM, Vesa SC, Ciumarnean L, Matei DM, et al. Cytokines genotype-phenotype correlation in nonalcoholic steatohepatitis. *Oxid Med Cell Longev.* 2017; 2017:4297206.
9. Metrakos P, Nilsson T. Non-alcoholic fatty liver disease--a chronic disease of the 21st century. *J Biomed Res.* 2018; 32:327-335.
10. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, et al. Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. *Gastroenterology.* 2002; 122:274-80.
11. Bianchi L. Liver biopsy in elevated liver functions tests? An old question revisited. *J Hepatol.* 2001; 35:290-4.
12. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. *World J Gastroenterol.* 2012; 18:727-35.
13. Dogru T, Ercin CN, Erdem G, Sonmez A, Tapan S, Tasci I. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. *Am J Gastroenterol.* 2008; 103:3217-8.
14. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. *Nat Med.* 2005; 11:183-90.
15. Haukeland JW, Damås JK, Konopski Z, Løberg EM, Haa- land T, Goverud I, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. *J Hepatol.* 2006; 44:1167-1174.
16. Mas E, Danjoux M, Garcia V, Carpentier S, Ségui B, Levade T. IL-6 deficiency attenuates murine diet-induced non- alcoholic steatohepatitis. *PLoS One.* 2009; 4:e7929.
17. Yamaguchi K, Itoh Y, Yokomizo C, Nishimura T, Niimi T, Fujii H, et al. Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice. *Lab Invest.* 2010; 90:1169-78.
18. Nozaki Y, Saibara T, Nemoto Y, Ono M, Akisawa N, Iwasaki S, et al. Polymorphisms of interleukin-1 beta and beta 3-adrenergic receptor in Japanese patients with nonalcoholic steatohepatitis. *Alcohol Clin Exp Res.* 2004; 28(8 Suppl Proceedings):106s-10s.

19. Lagathu C, Yvan-Charvet L, Bastard JP, Maachi M, Quignard-Boulangé A, Capeau J, et al. Long-term treatment with interleukin-1 β induces insulin resistance in murine and human adipocytes. *Diabetologia*. 2006; 49:2162-73.
20. Jager J, Gremeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1 β -induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. *Endocrinology*. 2007; 148:241-51.
21. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor- α : direct role in obesity-linked insulin resistance. *Science*. 1993; 259:87-91.
22. Lesmana CR, Hasan I, Budihusodo U, Gani RA, Krisnuhoni E, Akbar N, et al. Diagnostic value of a group of biochemical markers of liver brosis in patients with non- alcoholic steatohepatitis. *J Dig Dis*. 2009; 10:201-6.
23. Kumar R, Prakash S, Chhabra S, Singla V, Madan K, Gupta SD, et al. Association of pro-inflammatory cytokines, adipokines & oxidative stress with insulin resistance & non-alcoholic fatty liver disease. *Indian J Med Res*. 2012; 136:229-36.
24. Zahran WE, Salah El-Dien KA, Kamel PG, El-Sawaby AS. Efficacy of Tumor Necrosis Factor and Interleukin-10 Analysis in the Follow-up of Nonalcoholic Fatty Liver Disease Progression. *Indian J Clin Biochem*. 2013; 28:141-6.
25. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF- α or adiponectin? *Hepatology*. 2004; 40:46-54.
26. Lucero D, Zago V, Lopez GI, Graffigna M, Fainboim H, Miksztoewicz V, et al. Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome. *Clin Chim Acta*. 2011; 412:143-7.
27. Musso G, Gambino R, Durazzo M, Biroli G, Carello M, Faga E, et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. *Hepatology*. 2005; 42:1175-83.
28. Seo YY, Cho YK, Bae JC, Seo MH, Park SE, Rhee EJ, et al. Tumor Necrosis Factor- α as a Predictor for the Development of Nonalcoholic Fatty Liver Disease: A 4-Year Follow-Up Study. *Endocrinol Metab*. 2013; 28:41-5.